VDA 1214

Drug Profile

VDA 1214

Alternative Names: VDA1214

Latest Information Update: 26 May 2016

Price : $50

At a glance

  • Originator VidacPharma
  • Class Small molecules
  • Mechanism of Action Keratinocyte modulators; Voltage-dependent anion channel modulators; Voltage-gated potassium channel modulators; Voltage-gated sodium channel modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Research Solid tumours

Most Recent Events

  • 26 May 2016 Early research in Solid tumours in Israel (unspecified route) before May 2016 (VidacPharma pipeline; May 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top